Senolytics

Senolytics are compounds that selectively induce cell death in senescent cells by exploiting context-specific survival vulnerabilities, including BCL-2 family proteins, PI3K/AKT signalling and disruption of pro-survival complexes such as the FOXO4-p53 interaction. The vulnerabilities targeted are heterogeneous and compound-specific. Studied candidates include the dasatinib plus quercetin combination, fisetin and navitoclax. In animal models, intermittent senolytic dosing improves physical function and extends healthspan, but human evidence is still limited to early-phase trials and clinical use outside studies is not established.